Protagonist Therapeutics Inc (NASDAQ:PTGX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States. “

PTGX has been the topic of a number of other reports. BMO Capital Markets initiated coverage on shares of Protagonist Therapeutics in a research note on Tuesday, September 6th. They set an “outperform” rating on the stock. Leerink Swann initiated coverage on shares of Protagonist Therapeutics in a research note on Tuesday, September 6th. They set an “outperform” rating and a $17.00 price objective on the stock. Finally, Barclays PLC initiated coverage on shares of Protagonist Therapeutics in a research note on Tuesday, September 6th. They set an “overweight” rating and a $18.00 price objective on the stock.

Protagonist Therapeutics (NASDAQ:PTGX) opened at 24.95 on Thursday. The company’s market capitalization is $417.01 million. The firm has a 50 day moving average of $22.06 and a 200-day moving average of $18.12. Protagonist Therapeutics has a 52 week low of $10.02 and a 52 week high of $25.60.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Monday, November 14th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by $0.29. During the same period in the previous year, the business posted ($12.79) EPS.

COPYRIGHT VIOLATION WARNING: “Protagonist Therapeutics Inc (PTGX) Rating Increased to Hold at Zacks Investment Research” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and reposted in violation of international trademark and copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2016/12/01/protagonist-therapeutics-inc-ptgx-rating-increased-to-hold-at-zacks-investment-research.html.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Credit Suisse AG bought a new position in Protagonist Therapeutics during the third quarter worth approximately $358,000. Northern Trust Corp bought a new position in Protagonist Therapeutics during the third quarter worth approximately $425,000. Spark Investment Management LLC bought a new position in Protagonist Therapeutics during the third quarter worth approximately $889,000. BVF Inc. IL bought a new position in Protagonist Therapeutics during the third quarter worth approximately $7,924,000. Finally, RA Capital Management LLC bought a new position in Protagonist Therapeutics during the third quarter worth approximately $15,941,000.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (Protagonist) is a clinical-stage biopharmaceutical company. The Company has a technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs. Protagonist’s primary focus is on developing oral peptide drugs that specifically target biological pathways.

5 Day Chart for NASDAQ:PTGX

Receive News & Stock Ratings for Protagonist Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc and related stocks with our FREE daily email newsletter.